Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

NCT06742190 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT06742190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06742190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy
Lead sponsor
argenx
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 18, 2024
Completion date
December 31, 2029
Enrollment
154 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

mmn, multifocal motor neuropathy (mmn)